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Abstract
CITED2 (CBP/p300-interacting transactivator with Glu/Asp-rich C-terminal
domain, 2) is a ubiquitously expressed protein exhibiting a high affinity for the
CH1 domain of the transcriptional co-activators CBP/p300, for which it competes
with hypoxia-inducible factors (HIFs). CITED2 is particularly efficient in the
inhibition of HIF-1α-dependent transcription in different contexts, ranging from
organ development and metabolic homeostasis to tissue regeneration and
immunity, being also potentially involved in various other physiological
processes. In addition, CITED2 plays an important role in inhibiting HIF in some
diseases, including kidney and heart diseases and type 2-diabetes. In the
particular case of cancer, CITED2 either functions by promoting or suppressing
cancer development depending on the context and type of tumors. For instance,
CITED2 overexpression promotes breast and prostate cancers, as well as acute
myeloid leukemia, while its expression is downregulated to sustain colorectal
cancer and hepatocellular carcinoma. In addition, the role of CITED2 in the
maintenance of cancer stem cells reveals its potential as a target in non-small cell
lung carcinoma and acute myeloid leukemia, for example. But besides the wide
body of evidence linking both CITED2 and HIF signaling to carcinogenesis, little
data is available regarding CITED2 role as a negative regulator of HIF-1α
specifically in cancer. Therefore, comprehensive studies exploring further the
interactions of these two important mediators in cancer-specific models are sorely
needed and this can potentially lead to the development of novel targeted
therapies.
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Core tip: Hypoxia is a common feature of many cancers. In response to hypoxia,
hypoxia-inducible factor 1 (HIF-1) is stabilized and activates downstream target-genes
participating in crucial aspects of cancer biology, such as angiogenesis, cell survival,
glucose metabolism and invasion. CITED2 is a negative regulator of HIF with
demonstrated roles in various types of cancer. Therefore, CITED2 can potentially
modulate HIF effects in cancer and constitute a novel target for therapies. Herein, we
compile the roles reported for CITED2 in health and disease, namely through the
modulation of HIF activity. We also discuss the various context-dependent roles for
CITED2 in cancer.
Citation: Fernandes MT, Calado SM, Mendes-Silva L, Bragança J. CITED2 and the




CITED2, formerly known as melanocyte-specific gene related gene 1 and p35srj[1-4], is a
member of the CBP/p300-interacting transactivator with Glu/Asp-rich C-terminal
domain family of transcriptional modulators that includes also CITED1, CITED3 and
CITED4. These proteins, characterized by a conserved CBP/p300-interacting domain
located at the C-terminal domain, termed CR2 for conserved region 2 (Figure 1A), are
only conserved in vertebrates and contribute to several aspects of embryogenesis
and/or  to  normal  organ  function  in  adult  organisms[1,3,5-7].  CBP  and  p300  are
homologous nuclear phosphoproteins, ubiquitously expressed, that contain amongst
others, three highly conserved cysteine–histidine-rich domains (CH1, -2, and -3) and
function as transcriptional coactivators[8,9].  Although CITED proteins lack a DNA-
binding  domain,  they  usually  localize  in  the  nucleus  where  they  function  as
transcriptional modulators[10,11]. From all CITED members, CITED2 has been the most
studied, due to its pivotal roles in many different biological processes[5,6,12-14]. The CR2
of CITED2 is composed of 32 amino acids (residues 224 to 255) that contain a potent
transactivation domain (TAD), which is responsible for physically interacting with the
CH1 domain of CBP/p300, also known as TAZ1[3] (Figure 1A). The CH1 domain of
p300, which has an extremely high affinity for CITED2, also binds hypoxia-inducible
factors (HIF)-1α[15] and other transcription factors such as the NFκB p65 subunit[16],
p53, and MDM2[17]. Due to its interaction with CBP/p300, CITED2 was reported to act
both as a positive and a negative regulator of transcription. This function appears to
depend on whether CITED2 enables the interaction between CBP/p300 and other
transcription factors,  or  whether it  prevents  such interactions.  CITED2 has been
reported to be a transcriptional coactivator of TFAP2, SMAD2/3 (mediating TGFβ
signaling),  peroxisome  proliferator-activated  receptors,  ISL1,  amongst  other
factors[6,18-20]. Conversely, it acts as a transcriptional repressor through interfering with
the binding of transcription factors, such as HIF-1α and STAT2, with CBP/p300[21].
CITED2 is ubiquitously expressed and its expression is modulated by many biological
stimuli  including  lipopolysaccharide  and  cytokines,  such  as  interleukin  9  and
interferon gamma, in different cell types[2]. Most notably, CITED2 is highly inducible
by the HIFs under low oxygen/hypoxic conditions[3].
CITED2 AND THE MODULATION OF THE HYPOXIC
RESPONSE
The cellular response to hypoxia is critical for cell survival and is strictly regulated to
allow cells to adjust their needs during altered oxygen levels. HIFs play a central role
in systemic and cellular adaptation to decreased oxygen levels. These transcription
factors are heterodimeric proteins consisting of a hypoxia-inducible HIFα subunit,
and a  constitutively  expressed  HIFβ subunit,  also  known as  Aryl  Hydrocarbon
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Figure 1
Figure 1  Structure of CITED2 and its interplay with hypoxia-inducible factors to modulate the response to hypoxia. A: Schematic representation of CITED2,
hypoxia-inducible factor (HIF)-1α and CBP/p300. The conserved regions amongst CITED family members, and the serine-glycine rich junction domain unique to
CITED2 are indicated. Conserved regions 2 is the domain that characterizes the CITED proteins that contains a potent transactivation domain (TAD), which is
responsible for the physical interaction with the domain CH1 of CBP/p300, also represented. HIF-1α has two TADs, namely, a N-terminal TAD and a C-terminal TAD,
which are responsible for the transcriptional activity under hypoxia. To this end, HIF-1α binds to the CH1 region of p300, but CITED2 was shown to compete out HIF-
1α for the binding to the same region, and to interfere with hypoxia-driven transcription; B: Model for CITED2, HIF-1α and CBP/p300 in hypoxia-responsive gene
regulation. In normal levels of oxygen (normoxia), HIF-1α is hydroxylated at two proline residues within its oxygen-dependent degradation domain, which marks HIF-
1α for proteasome degradation. In normoxia, CITED2 binds to CBP/p300 in the nucleus regulating the expression of target-gene. In addition, part of CITED2 proteins
is ubiquitinated by FBXL5 and degraded by the proteasome. In hypoxia, HIF-1α is no longer hydroxylated, which prevents its degradation by the proteasome.
Consequently, HIF-1α translocate and accumulates in the nucleus to associate with the HIFβ subunit to bind to specific Hypoxia-Response Elements in hypoxia-
regulated genes. CITED2 competes with HIF-1α for the binding to the CH1 region of CBP/p300 and interferes with hypoxia-driven transcription. CR: Conserved
regions; SRJ: Serine-glycine rich junction; TAD: Transactivation domain; HIF: Hypoxia-inducible factor; NAD: N-terminal TAD; CAD: C-terminal TAD.
Receptor Nuclear Translocator or ARNT[22,23]. Three oxygen-sensitive HIF subunits
have been identified to date, HIF-1α, HIF-2α, and HIF-3α, and all of them dimerize
with HIF-1β, originating HIF-1, HIF-2, and HIF-3 heterodimers, respectively[24]. HIF-
1α, HIF-2α and HIF-3α have a high degree of sequence homology but are significantly
distinct in their functions. For instance, the hypoxic response may be exclusively
controlled by one or the other oxygen-sensitive HIF isoforms in different contexts[25].
Since several studies have reported a role for CITED2 in hypoxia, particularly through
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the inhibition of the HIF-1α, we will focus the review on this isoform.
HIF-1α cellular  levels  are  essentially  regulated through alterations  in  protein
stability. In normal oxygen levels (normoxia), HIF-1α (and also HIF-2α) is constantly
expressed, but rapidly degraded through the ubiquitin-proteasome pathway, in an
oxygen-dependent manner[26-29]. HIF-1α contains an oxygen-dependent degradation
domain  (ODDD)  which  is  hydroxylated  at  two  proline  residues  by  prolyl-4-
hydroxylase domain proteins (PHDs),  known as oxygen sensors[30,31].  The prolyl-
hydroxylation allows the interaction of HIF-1α with the von Hippel-Lindau (VHL)
protein,  which is  the  substrate  recognition component  of  an E3 ubiquitin  ligase
complex, leading to HIF-1α degradation by the proteasome[32-36] (Figure 1B). HIF-1α
has two TADs, namely, a N-terminal TAD (NAD) located within the ODDD and a C-
terminal TAD (CAD), which are responsible for the transcriptional activity of HIF-1α
(and HIF-2α) under hypoxia (Figure 1A). In addition to the ODDD regulation, which
prevents the stability of HIF proteins,  a second oxygen-dependent mechanism is
responsible  for  the  inhibition  of  the  HIF-1α  transcriptional  activity.  Indeed,  an
asparagine residue located in the HIF-1α CAD (and HIF-2α CAD), is the target for
hydroxylation by an oxygen-dependent hydroxylase named factor inhibiting HIF or
FIH-1[21,37].  The  hydroxylation  of  this  asparagine  residue  interferes  with  the
recruitment of the CBP/p300 in normoxia[38,39].  Therefore,  molecular mechanisms
involving the hydroxylation of ODDD and CAD synergize to neutralize HIF-1α (and
HIF-2α) transcriptional activity in normoxia.
In  hypoxia,  the  prolyl-4-hydroxylase  domain  proteins  lose  their  ability  to
hydroxylate  HIF-1α,  which  prevents  its  interaction  with  VHL and  proteasomal
degradation. Consequently, HIF-1α translocates and accumulates in the nucleus, and
associates with the HIFβ subunit  to form HIF-1 and to bind to specific  hypoxia-
response elements in hypoxia-regulated genes (Figure 2B). Thus, HIF-1 is responsible
for  transcriptional  programs  that  promote  erythropoiesis,  glycolysis,  and
angiogenesis, between other processes[22,40,41]. It was previously demonstrated that HIF
TADs play different  roles  in  hypoxia responses  by activating distinct  subsets  of
genes[42,43]. Nevertheless, the expression of hypoxia-responsive genes is only efficient
when HIF-1 recruits CBP/p300[15].
CITED2 was shown to compete with HIF-1α for the binding to the CH1 region of
CBP/p300, and to interfere with hypoxia-driven transcription[3] (Figure 1A). Structural
studies have shown that both HIF-1α and CITED2 transactivation domains interact
with the CH1 domain of CBP/p300 through helical motifs that flank a conserved
LP(Q/E)L sequence  to  achieve  high affinity  binding,  displacing  each other  in  a
feedback loop during the hypoxic response[10,43-45]. More specifically, Berlow et al[45]
have shown that CITED2 is able to displace HIF-1α by forming a transient ternary
complex with TAZ1/CH1 and HIF-1α, competing for a shared binding site through
its LPEL motif, resulting in a TAZ1 conformational change that increases the rate of
HIF-1α dissociation, even at modest concentrations of CITED2[45]. Moreover, CITED2
is itself an hypoxia-stimulated gene through the action of HIF-1α and HIF-2α[3,46].
Thus, CITED2 is thought as a negative feedback regulator of HIF-1α, contributing for
the cellular mechanisms that attenuate the hypoxic response.
In addition to reducing the hypoxia-induced activation of HIF CAD-dependent
genes, CITED2 also interferes with HIF NAD-dependent gene activation. Indeed,
Yoon et al[47] showed that NAD interacts with the CH1 and CH3 domains of p300 and
these were both required for NAD-dependent transactivation. Interestingly, CITED2
was shown to be able to inactivate NAD by interfering with the NAD-CH1 binding,
but  not  with  the  NAD-CH3  interaction[47].  Nevertheless,  CITED2  is  a  powerful
inhibitor HIF-1α transcriptional activity by blocking the recruitment of CBP/p300
through  both  NAD  and  CAD.  Remarkably,  the  same  authors  found  that  NAD
activation through binding to p300 could be blocked not only by CITED2 but also by
the VHL protein, supporting the hypothesis that NAD might be controlled by VHL
protein during normoxia and by CITED2 during hypoxia[47]. In this context, we have
reported  another  mechanism  supporting  a  role  for  CITED2  in  HIF-1α  NAD
inactivation in normoxia. Indeed, we have demonstrated that F-Box and leucine-rich
repeat protein 5 (FBXL5) overexpression in cells,  results  in CITED2 degradation,
which enabled the transcriptional activity of HIF-1α through the NAD in normoxia
(Figure 1B). In fact, we showed that CITED2 and FBXL5 proteins interact, and FBXL5,
which is a substrate adaptor protein part of E3 ubiquitin ligase complexes, triggers a
proteasome-dependent degradation of CITED2 and consequently contributes to the
modulation of gene expression mostly through HIF-1α NAD[11].
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Figure 2
Figure 2  Roles of CITED2 in homeostasis and cancer. CITED2-dependent modulation of hypoxia-inducible factor (HIF) is fine-tuned to control physiological
processes such as development, tissue regeneration and immunity. Abrogation of CITED2/HIF-1α homeostasis may lead to the initiation, and/or disease progression
depending on the cellular context. Cancer may be one these diseases, in which CITED2 and HIF-1α intervene to control tumor growth, drug resistance and
metastization. HIF: Hypoxia-inducible factor.
CITED2 AND HYPOXIA IN PHYSIOLOGICAL PROCESSES
The role of CITED2 in regulating HIF1 activity was shown to be also essential in vivo.
Indeed, Cited2 knockout mouse embryos died in utero at around mid to late gestation
and displayed multiple  developmental  anomalies,  such as  heart  malformations,
adrenal agenesis and neural tube defects[6]. Interestingly, the hearts of Cited2-null
embryos displayed elevated expression of  HIF-1α target  genes,  such as vascular
endothelial growth factor (VEGF), glucose transporter 1, and phosphoglycerate kinase
1. These genes were also upregulated in Cited2-depleted mouse embryonic fibroblasts
under hypoxic conditions[48]. Interestingly, a normalized expression of HIF-1α target
genes and part of the heart defects were rescued upon the heterozygous deletion of an
Hif1a allele in Cited2-null embryos[48,49]. This indicated that a hyperactivity of HIF-1α
in Cited2-null embryos is, at least in part, responsible for the cardiac developmental
anomalies  observed.  Cited2-deficient  mouse embryos present  also defects  in the
developing eye and showed an excessive and disorganized hyaloid vasculature with
increased VEGF expression[50]. Further experiments showed that deletion of Hif1a in
the lens could specifically rescue the previous phenotype, supporting the notion that
Cited2 is required for the proper hyaloid vascular system regression through negative
modulation of HIF-1 signaling during eye development[50]. Cited2 was also reported to
modulate HIF-dependent expression of  VEGF in the nucleus pulposus of  the rat
intervertebral disc, most likely contributing for the mechanism by which the cells of
the nucleus pulposus survive in a hypoxic environment[51].
Normal  hematopoiesis  also  relies  on  the  correct  function  of  CITED2.  Indeed,
CITED2 is crucial for the maintenance of the hematopoietic stem cell (HSC) pool in the
bone marrow (BM), and its conditional deletion in the hematopoietic system resulted
in a dramatic loss of adult HSCs and primitive progenitor cells, ultimately leading to
BM failure[52].  In  addition,  it  was reported that  Cited2-deficient  HSCs presented
impaired quiescence and reconstitution capacity, which could be partially rescued by
additional deletion of HIF-1α[53]. Therefore, Cited2 is able to regulate HSC quiescence
through  a  HIF-1-dependent  mechanism,  although  other  HIF-1-independent
mechanism(s)  may be  also  involved in  this  context[53].  In  addition,  CITED2 was
reported to be involved in immunity, more specifically by repressing macrophage-
mediated inflammation. Thus, Cited2 deficiency may enhance proinflammatory gene
expression  through  stabilization  of  HIF-1α  in  macrophages.  Furthermore,  the
inhibition  of  HIF-1α  in  Cited2-deficient  macrophages  completely  reversed  the
elevated  proinflammatory  cytokine/chemokine  gene  expression[54].  Thus,  the
repressive CITED2 action on HIF-1α activity is crucial for many aspects of mouse and
rat development, as well as adult homeostasis.
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CITED2 AND HYPOXIA IN DISEASE
CITED2 was shown to be involved in the regulation of the hypoxic response in the
context of diseases (Figure 2). Using animal models of chronic kidney disease and
heart failure, Tanaka et al[55] have implicated CITED2 in the negative regulation of
HIF-target genes,  and consequently in suppressing the hypoxic response.  In this
context,  the  accumulation  of  indoxyl  sulfate  (an  uremic  toxin)  in  the  systemic
circulation due to a reduced renal clearance, resulting in renal and cardiovascular
dysfunction[56], was due to CITED2 stabilization and consequent HIF-1α inhibition[55].
Also, in a type 2 diabetes animal model, Wang et al[57]  have shown that, although
insulin is  able to downregulate CITED2 in endothelial  cells,  the vascular insulin
resistance characteristic of this disease contributes to the upregulation of CITED2,
which impairs HIF signaling and, consequently aborts angiogenesis[57].
In cancer, HIF-1 activates the transcription of genes that are involved in crucial
aspects  of  cancer  progression,  including  angiogenesis,  cell  survival,  glucose
metabolism,  invasion  and  cell  self-renewal [58 ,59].  In  several  types  of  cancer,
intratumoral  hypoxia  and  genetic  alterations  were  reported  to  lead  to  HIF-1α
overexpression, which is associated with increased patient mortality. Therefore, the
inhibition of HIF-1 activity is  regarded as a promising therapeutic approach[22,58].
Importantly, the intricate HIF pathway also initiates anti-tumorigenic mechanisms
that lead to cell cycle arrest or cell death[60,61],  illustrating the need for a stringent
control of the hypoxia response. Thus, HIF feedback regulators help to adjust and
adapt HIF-activated responses to the fluctuating oxygen concentrations within tumors
and to restrict the tumor-suppressing components of the HIF pathway. Therefore,
given their  role in cancer biology,  HIF feedback regulators such as CITED2 may
represent attractive targets for cancer therapy[62].
CITED2 AND HYPOXIA IN CANCER
The potential involvement of CITED2 in cancer was unveiled since it  was demo-
nstrated to be a transforming gene in Rat1 cells. Indeed, when overexpressed, Cited2
induced loss of cell contact inhibition, anchorage-independent growth, and tumor
formation  in  nude  mice[2].  Since  this  first  publication  describing  CITED2,  the
dysregulation of its expression has been widely associated with aggressiveness and
prognosis of several cancers including, among others, breast,  colon, prostate and
gastric cancers, as well as acute myeloid leukemia.
CITED2 in breast cancer
Breast cancer (BC) is the most frequent cancer affecting women worldwide, and the
second leading cause of cancer-related deaths in women[63]. Studies using both animal
models  and  human  BC  primary  samples  showed  that  CITED2  expression  was
elevated in primary tumors and metastasis, when compared to normal mammary
epithelium[64,65]. However, the reports on CITED2 function and prognostic in BC are
discrepant. Indeed, high CITED2 mRNA levels were associated with a clinical benefit
in tamoxifen-treated BC and a prolonged metastasis-free survival in patients who had
not received adjuvant systemic therapy[66].  More recent studies, showed that high
CITED2 levels in primary tumors, when compared to normal mammary epithelium,
were inversely correlated with patient survival[64,67]. In addition, high levels of CITED2
expression were shown to significantly increase the proliferation and migration of
MCF-7 and SKBR-3 BC cell lines in culture[65]. By studying the possible mechanism
involved in tumor growth and metastization, Jayaraman et al[68] have shown that the
expression of IKKα and other NF-κB targets, with recognized roles in the metastatic
process, were significantly decreased in both MDA-MB-231 and MDA-MB-468 cell
lines following CITED2 knockdown. Moreover, the restoration of IKKα expression in
CITED2-depleted  cells,  restored  their  invasive  capacity[68].  In  addition,  CITED2
silencing was also associated with reduced primary tumor growth, influencing the
tumor vasculature by preventing TGF-β induction of VEGFA via CITED2 recruitment
to the VEGFA promoter[69]. Interestingly, the authors reported that HIF-1α was not
involved in this process[69]. This is a surprising observation, since increasing VEGFA
expression and tumor vasculature are prime roles usually attributed to HIF-1α and
expected to be counteracted by CITED2. Therefore, this report supports the notion
that  negative  regulation  of  HIF-1α  by  CITED2  may  be  cell-type  dependent  or
somehow impaired in breast cancer cells. Alternatively, CITED2 may in this case act
as  co-activator  of  other  transcription  factors,  such  as  SMAD2/3[18],  which  are
mediators  of  TGF-β  signaling  pathway,  or  TFAP2A,  showed  to  cooperate  with
CITED2 for normal vascularization of the myocardium during heart development[70].
Other  studies  also  reported  a  reduction  in  primary  tumor  growth  due  to  the
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attenuation of tumor-associated macrophage (promoting tumor development and
progression) recruitment in response to CITED2 depletion in cancer cells and the
consequent  downregulation  of  the  macrophage  chemoattractant  CCL20[71].  This
suggests  that  CITED2 promotes  tumor-associated  macrophage  recruitment  and
infiltration in breast tumors. Metastases are the ultimate cause of death in BC patients
and have a  special  tropism to develop in the bone.  Although the molecular  and
cellular mechanisms behind BC cell homing and colonization of the bone are not fully
understood,  it  was  shown that  intracardiac  injection of  CITED2-depleted NT2.5
mammary tumor cells in neu-N immunocompetent mice inhibited the establishment
of bone metastasis and osteolysis, suggesting that CITED2 can promote osteotropism
in BC[67]. CITED2 was also implicated in the acquisition of resistance to epirubicin and
5-fluorouracil therapies by inhibiting p53 accumulation[65], as well as resistance to
tamoxifen, because it is a transcriptional co-activator of the estrogen receptor in breast
cancer cells[64].
Altogether, these studies show that CITED2 is overexpressed in BC, contributing to
prognosis, invasion and responsiveness to therapy. Moreover, CITED2 was shown to
be induced by FOXO3a and to act as a transcriptional co-factor regulating HIF1-
induced  apoptosis  in  mouse  embryonic  fibroblasts  and  MCF-7  BC  cells [72].
Nevertheless, a role for CITED2 in mediating HIF effects in the context of BC was not
clearly reported. Interestingly, its family member, CITED4, was found to be expressed
in human BC cell lines and to be inversely associated with HIF-1α activity[73]. In fact,
CITED4 was shown to be either expressed at low levels in the nucleus or trapped in
the cytoplasm during breast tumor progression, implying in both circumstances that
CITED4 had lost its ability to inhibit HIF-1α transcriptional activity, allowing the
progression of the tumor size, grade and angiogenesis[73].
Cited2 and colorectal cancer
Colorectal cancer (CRC) is the second most deathly cancer worldwide[74]. CRC usually
metastasizes to the liver, which is the cause of high mortality rates. In contrast to what
was reported for BC, CITED2 depletion in CRC was associated with enhanced cell
invasiveness[75]. Bai et al[75] have shown increased matrix metalloproteinase 13 (MMP-
13) expression following CITED2 knockdown in RKO and SW480 CRC cell  lines,
suggesting  that  CITED2  may  downregulate  MMP-13  expression  and  limit
invasiveness  in  CRC[75].  Notwithstanding,  neutralizing  MMP-13  activity  with  a
monoclonal antibody, only slightly reduced the invasive capacity of SW480 cells
expressing  reduced levels  of  CITED2,  suggesting  that  other  changes  in  CITED2
knockdown cells also contributed to the altered invasiveness of these cells[75].
These data suggest that downregulation of CITED2 might have an important role in
CRC progression but  the mechanism mediating these effects  is  not  fully known.
Therefore, further studies should be undertaken to assess how CITED2 expression is
modulated and whether low levels of CITED2 expression lead to increased HIF-1α
transcriptional activity. Also using the SW480 cell line, Rogers et al[76] reported that
CITED4 gene silencing modulated adherens/tight  junction gene expression and
reduced cell proliferation, without affecting apoptosis, colony formation, migration,
invasion or adhesion[76].
Cited2 and prostate cancer
Prostate cancer (PC) is the most frequent cancer in men. More than half of the patients
with PC present a translocation originating a fusion between the androgen-responsive
gene TMPRSS2 and ETS (erythroblast transformation-specific)-family transcription
factor genes such as ERG (ETS-related gene) and ETV1[77]. It has been speculated that
CITED2 might be involved in PC, since its expression can be activated by ELK-1,
another ETS family member[46], that is able to recruit androgen receptor to promote PC
cell growth[78]. By testing this hypothesis, Shin et al[79] found that ERG was specifically
upregulated  as  a  consequence  of  the  TMPRSS2–ERG  gene  fusion  in  PC  cells.
Interestingly, this fusion also upregulated CITED2, which was reported to promote
post-translational modifications in nucleolin to enhance the metastatic potential of PC
cells[79]. The metastatic facilitation occurs through AKT upregulation and a consequent
increase of the epithelial–mesenchymal transition and invasion potential[79]. Therefore,
CITED2-nucleolin-AKT signaling pathway should be considered as a potential target
for therapies aiming to treat PC and prevent metastasis. A role for CITED2 in the
regulation of HIF-1α in prostate cancer was not evaluated although in vitro studies
have previously shown that CITED2 is highly induced by hypoxia in DU145 prostate
carcinoma cells[80].
Cited2 and gastric cancer
Gastric  cancer  (GC) is  a  silent  and slow developing cancer  that  usually  remains
undetected until it reaches advanced stages[81]. The studies of Tang et al[82] using both
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GC cell lines and human primary samples showed that those cells can be categorized
based on the CITED2 expression levels. In addition, CITED2 knockdown in cell lines
with high CITED2 expression led to a decrease of their proliferation, mitochondrial
membrane  potential,  colony  formation,  and  an  induced  cell  cycle  arrest  and
apoptosis[82]. These results suggest that CITED2 can be considered as a good target for
therapy in GC. Additionally, it was reported that GC cells with low expression of
CITED2 are chemoresistant to anthracyclines. Interestingly, the pretreatment of GC
cells  with  low  expression  of  CITED2  with  LBH589,  an  HDAC  inhibitor,  could
reactivate  the  expression  of  CITED2  and  sensitized  them  to  chemotherapeutic
drugs[83]. HIF-1α has been shown to be involved in various processes in GC[84], but the
impact of CITED2 modulation on its activity remains to be established.
Cited2 and hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths
worldwide[85]. CITED2 plays an important role in liver development, as indicated by
knockouts of CITED2 in mice, which present fetal liver hypoplasia, due to increased
cell  apoptosis  and  disrupted  cell-to-cell  contact[86].  In  HCC  cells,  CITED2  was
identified  as  a  direct  activator  of  PPARγ,  which  possesses  a  tumor  suppressive
activity. CITED2 was significantly downregulated in primary HCCs when compared
with  their  adjacent  non-tumor  tissues.  In  addition,  CITED2  knockdown  in  the
hepatocyte cell line LO2 and the HCC cell line Hep3B significantly increased cell
viability and clonogenicity[87]. This was attributed to an increased cell cycle transition
from G1 to S phase, concomitant with the downregulation of the cyclin-dependent
kinase inhibitors p15INK4B, p21Wat1/Cip1, and p27Kip1 and the upregulation of cyclin D1
expression[87]. In contrast, overexpression of CITED2 in HepG2 and BEL7404 HCC cell
lines significantly suppressed cell  growth by increasing p21Wat1/Cip1  and p27Kip1[87].
MicroRNAs have been reported to be promising biomarkers for HCC[88]. miR-1468, a
novel cancer-related MicroRNAs which overexpression was associated with a poor
prognosis in HCC patients, was reported to inhibit PPARγ/AKT signaling pathway
through direct suppression of CITED2 and Up-frameshift protein 1, consequently
promoting cell proliferation[89]. Jiang et al[90] also found that miR-182-5p is upregulated
in liver cell lines exposed to the human carcinogen trichloroethylen, which in turn
inhibits  CITED2  and  enhances  cell  proliferation[90].  These  data  reinforce  the
antiproliferative effect of CITED2 in HCC. Interestingly, CITED2 was found to be
degraded  via  the  ubiquitin-proteasome  system  and  thus  to  be  stabilized  by
proteasome  inhibition[91].  Therefore,  although  HIF-1α  can  be  upregulated  by
proteasome inhibition as shown in Hep3B cells and HEK293 embryonic kidney cells,
its activity is reduced due to CITED2 interference with HIF-1α binding to p300 in
hypoxic conditions[91]. This mechanism sheds light on how proteasome inhibitors may
inhibit HIF-1α, which can be used as an anticancer therapy. Despite the knowledge of
this important role for CITED2 in mediating the paradoxical responses of HIF-1α to
proteasome inhibition, the regulation of the hypoxic response by CITED2 and its
contribution to the pathogenesis of HCC remains elusive.
Cited2 and acute myeloid leukemia
Acute myeloid leukemia (AML) is a heterogeneous disease in which genetic and
epigenetic factors contribute to the abnormal proliferation and differentiation of
myeloblasts, generating a clonal population in the bone marrow[92].  An important
regulator of hematopoiesis is the PU.1 transcription factor, which is expressed at low
levels in hematopoietic stem and progenitor cells[93] and is crucial for hematopoietic
stem and progenitor cells maintenance and differentiation of the myeloid lineage[94-98].
In AML, PU.1 is usually dysregulated by mutations, translocations, and alterations in
signal transduction, which promotes the accumulation of immature blasts[99,100]. PU.1
negatively regulates the expression of CITED2, by binding to multiple ETS-binding
sites in the CITED2 promoter[101]. As shown by conditional knockout studies, Cited2 is
essential for HSC maintenance. In contrast, the lack of Cited2 was not so evident in
more committed cells[52]. Andersson et al[102] have shown that AML cells have high
levels of CITED2 expression[102]. In addition, Korthuis et al[101] have shown that CITED2
overexpression alone is enough to maintain the primitive CD34+CD38− HSC pool by
decreasing apoptosis and enhancing quiescence, proving that CITED2 is crucial for
AML maintenance[101]. More recently, Mattes et al[103] have reported that loss of CITED2
impairs AML cell survival via p53-mediated apoptosis by interfering with the AKT
signal  transduction  pathway.  Moreover,  the  same  authors  have  shown  that
simultaneous upregulation of CITED2 and downregulation of PU.1 enhances the
lifespan of HP hematopoietic stem and progenitor cells (HPSCs), which makes them
more prone to full leukemic transformation[104]. These results indicate that CITED2
plays an important role in the pathogenesis of AML and it should be considered as a
target for AML therapy. Interestingly, HIF-1α was reported to play also important
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roles in the self-renewal of AML leukemic stem cells and was indicated as a potential
therapeutic target for eliminating these leukemic stem cells[105-107], but a possible role
for CITED2 in this context was not explored.
Cited2 and lung cancer
Lung cancer is the leading cause of cancer-related death and approximately 80% of
lung cancers are identified as non-small cell lung carcinoma (NSCLC)[108]. It is known
that  TGF-α  and  TGF-β  are  two  key  cytokines  that  regulate  proliferation  and
quiescence, respectively, of lung epithelial cells during both normal and neoplastic
lung development[109]. CITED2 plays also an important role in lung development, as
demonstrated by the fact that CITED2 knockout mice display abnormal fetal lung
development[13].  Chou  et  al[110]  showed  that  in  lung  cancer,  CITED2  works  as  a
molecular switch for TGF-α proliferation and TGF-β quiescence stimuli in a MYC-
dependent  pathway.  CITED2  was  shown  to  recruit  p300  to  induce  MYC-p300-
mediated transactivation of E2F3, leading to increased G1 to S cell cycle progression.
Moreover,  CITED2  was  able  to  inhibit  cellular  quiescence  by  promoting  MYC-
mediated suppression of p21CIP1[110]. Moreover, the same authors also observed that
CITED2/MYC/E2F3/p21CIP1 pathway was activated in patients with NSCLC with a
poor prognosis[110].
Cited2 and cancer stem cells
The previous studies support the notion that CITED2 has context-dependent roles in
cancer (Table 1). Although less extensively, CITED2 has also been shown to play a
role  in  some  other  cancers,  such  as  undifferentiated  pleomorphic  sarcoma,
osteosarcoma, thyroid, and ovarian cancers[111-114]. CITED2 is also likely to play a role
in an important aspect of tumor development related to cancer stem cells (CSCs). It is
currently accepted that tumors originate from CSCs, which may derive from normal
stem or progenitor cells that have lost the ability to self-regulate proliferation and
quiescence[115,116].  Interestingly,  an  abnormal  expression  of  core  pluripotency
transcription factors, such as OCT4, SOX2, NANOG, TBX3 and KLF4, has also been
associated with CSCs, suggesting that the expression of pluripotent gene regulatory
network factors may contribute to the conversion of normal cells into CSCs[117].  In
murine embryonic stem cells, Cited2 controls the expression of Nanog, Tbx3, Klf4 and
Oct4[118,119], and in adult stem cells it was associated with self-renewal, survival and
quiescence[52,120,121]. Moreover, the CITED2-target gene BMI1, was shown to be involved
in various CSC functions[122-124].  Thus,  in particular  circumstances,  an anomalous
increase  of  CITED2 expression may contribute  to  uncontrolled self-renewal  and
proliferation of stem cells and originate CSCs. Supporting this notion, a subset of
patients with AML present an aberrantly elevated expression of CITED2 in CD34-
positive  leukemic  cells  compared  to  normal  cells[101].  The  imbalanced  CITED2
expression due to a failure of PU.1 repression during normal myelopoiesis is likely to
promote the initiation and maintenance of leukemia, and potentiate the establishment
of a subset of multipotent leukemic stem cells[101]. On the other hand, patients with
NSCLC expressing CITED2/MYC/E2F3/p21CIP have a poor prognosis[110], but CITED2
was demonstrated to repress the expression of CSCs markers in NSCLC-stem cells
and enhance their sensitivity to ionizing radiations in combination with butyrate
treatment[125]. Therefore, the potential role played by CITED2 in the generation and
maintenance of CSCs may vary with the nature of the tumor. Interestingly, increasing
evidence indicates that HIFs regulate the sub-populations of CSCs in BC, CRC, and
AML, for instance[126].  Therefore, studies to determine whether abnormal levels of
CITED2 are important in CSC functions and weather CITED2-mediated inhibition of
HIF signaling is on the basis of these functions should be pursued.
CONCLUSION
Altogether, the previous studies have shown that CITED2 is expressed ubiquitously
and exhibits  a  very  high  affinity  for  the  CH1 domain  of  the  transcriptional  co-
activators CBP/p300, for which it competes with HIFs. CITED2 plays an important
role in inhibiting HIF-1α in some diseases reviewed here, and may play a role in
many others, since altered HIF activity was reported also in stroke, heart attack, and
pulmonary hypertension, for example. In the particular case of cancer, CITED2 has
been reported to have both oncogenic and tumor suppressive properties, depending
on the cell/tumor type and treatment,  like it  was also shown for HIF. A role for
CITED2 in the maintenance of CSCs was also unveiled in some cancers and seems to
be  also  context-dependent.  On  the  other  hand,  HIF  signaling  in  CSCs  is  well
established. Despite evidence linking both CITED2 and HIF functions independently
to several aspects of cancer, little data linking the interplay between these two factors
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Table 1  Effects of CITED2 in different cancer
Cancer type CITED2 effect Biological context Cellular effects Interaction with HIF-1α Ref.











Colorectal cancer Downregulation Cell lines (RKO; SW480) Migration; invasion Not determined
[75]
Prostate cancer Overexpression Cell lines (LNCaP;
VCaP; DU145; PC-3; C4-
2B; 22RV1); primary
tumor; mouse xenograft
Invasion; metastization Not determined
[79]























Overexpression Primary cell cultures;

















in  these  processes  is  available.  Therefore,  comprehensive  studies  exploring  the
interactions between CITED2 and HIF-1α, which are important mediators in cancer,
are sorely needed. A better understanding of this interplay may potentially lead to
novel strategies for the development of innovative, targeted therapies.
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